Abbreviations: FBS, fetal bovine serum; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; TNF, tumor necrosis factor; ELISA, enzyme-linked immunosorbent assay.
INTRODUCTION
Paclitaxel is the active constituent of Taxol ® , a clinically utilized anticancer agent which either alone or in combination has demonstrated activity against a wide range of human cancers. 1 A complex diterpene first isolated from the bark of the Pacific Yew tree (Fig. 1 ), paclitaxel has been demonstrated to be cytotoxic in vitro as a result of its ability to polymerize tubulin and stabilize the resulting microtubules against depolymerization. [2] [3] [4] [5] More recently, however, paclitaxel has been demonstrated to reproduce many of the effects of Gram-negative bacterial lipopolysaccharide (LPS) on murine macrophages, resulting in the activation of numerous intracellular signaling pathways that culminate in gene expression and cytokine secretion (reviewed by Vogel et al. 6 ). Specifically, paclitaxel shares with LPS the ability to induce, in murine macrophages, activation of Lyn kinase activity, 7 tyrosine phosphorylation of Shc and its association with Grb 2, 8 tyrosine phosphorylation of MAP kinases, [9] [10] [11] [12] translocation of NF-κB, 13, 14 and induction of gene expression. 9, 10 In addition, in interferon-primed macrophages, paclitaxel, like LPS, can serve as a 'second signal' for the synergistic induction of iNOS mRNA expression, nitric oxide (NO • )
The anti-tumor agent, paclitaxel (active ingredient of Taxol ® ), is best recognized for its ability to bind to microtubules and to block cell division. However, it has more recently been demonstrated to mimic the varied effects of bacterial lipopolysaccharide (LPS) in murine macrophages, actions that appear to be dissociable from its well-characterized β-tubulin binding capacity. Secretion of tumor necrosis factor alpha (TNFα) and induction of TNFα gene expression were assessed in macrophages treated with paclitaxel analogs. Two structural modifications resulted in elevated TNFα mRNA and protein secretion: (i) the presence of a cyclopropane carboxylate ester at C-4 rather than an acetate; or (ii) deoxygenation of the C-7 position. Certain modifications essentially eliminated activity: derivatization of the side chain 2′ hydroxy group to form an ethyl carbonate, the presence of a benzoate at C-4 rather than an acetate, or de-acetylization to leave a free hydroxy group at the C-10 position. Substitution of the phenyl group at the 3′ carbon position of the side chain with a 2-furyl group or the presence of a 2-or 3-pyridine carboxylate moiety at C-2 rather than a benzoate also resulted in a significant reduction in TNFα. These structure-activity relationships can be distinguished from those that affect the cytotoxic effects of paclitaxel which are attributable to its microtubule binding activity. secretion, and NO • -dependent tumoricidal and microbicidal activities. 15, 16 However, not all taxanes exhibit LPSmimetic activity, and several studies on the structureactivity relationships have been carried out. 6, [17] [18] [19] [20] [21] A dissociation between paclitaxel's LPS-mimetic effects on macrophage signaling versus its microtubule stabilizing effects in vitro and in cells has been reported. For example, paclitaxel analogs, such as docetaxel (Taxotere ® ) and mimics, such as Epothilone, possess higher affinities for β-tubulin than paclitaxel and compete with paclitaxel for the same binding site on microtubules, yet fail to elicit LPS-mimetic activity in murine macrophages. 17, 19, 20 In contrast to the cytotoxic effects of paclitaxel, its LPSmimetic activities are relatively species-specific, with most of the work having been carried out in murine macrophages. 6 Only recently has paclitaxel been shown to elicit cytokine secretion from unprimed human monocytes; 22 however, unlike the LPS-mimetic activity of paclitaxel in murine macrophages, its activity on human cells appears to be quite limited.
In this study, a series of taxane analogs (Figs 2-4) which display widely disparate in vitro anti-tumor cytotoxic activities, was compared to paclitaxel for the ability to induce TNFα secretion and TNFα steady-state mRNA. The data provide clear evidence for structure-activity relationships among the various taxane analogs tested.
MATERIALS AND METHODS

Reagents
Escherichia. coli K235 LPS, used in our previous studies 7, 9, 15, 17 on Taxol's activity as an LPS-mimetic, was used as a positive control in all experiments. This preparation is essentially protein-free (< 0.008%). Paclitaxel was obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute (Bethesda, MD, USA). All other analogs tested were synthesized by the Discovery Chemistry Department, Bristol Myers Squibb Co., (Wallingford, CT, USA) and were evaluated for in vitro cytotoxicity versus HCT 116 human colon carcinoma cells (Table 1) .
To test the activity of these taxane analogs as potential LPS-mimetics in murine macrophage cultures, each was solubilized in DMSO to a stock concentration of 20 mM. Stock taxane solutions were further diluted in buffered RPMI containing 2% fetal bovine serum (FBS) to derive the desired concentrations of taxanes utilized in these studies.
Macrophage culture conditions
Male and female, 4-6-week-old, C3H/OuJ mice (The Jackson Laboratory, Bar Harbor, ME, USA) were injected Cytotoxicity was assessed in HCT116 human colon carcinoma cells by XTT (2,3-bis(2-methoxy-4-nitro-5sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide assay. 32 Cells were plated at 4,000 cells/well in 96-well microtiter plates and 24 h later, drugs were added and serial diluted. The cells were incubated at 37°C for 72 h, at which time the tetrazolium dye, XTT, containing phenazine methosulfate, was added. A dehydrogenase enzyme in live cells reduces the XTT to a form that absorbs light at 450 nm which can be quantitated spectrophotometrically. The greater the absorbance the greater the number of live cells. The results are expressed as an IC 50 which is the drug concentration required to inhibit cell proliferation (i.e. absorbance at 450 nm) to 50% of that of untreated control cells.
i.p. with 3 ml of 3% fluid thioglycollate. After 4 days, peritoneal exudate cells were extracted by peritoneal lavage with 0.9% NaCl, washed once, and resuspended in RPMI 1640 medium supplemented with 2 mM glutamine, 30 mM HEPES, 0.3% NaHCO 3 , 100 IU/ml penicillin, 100 µg/ml streptomycin and 2% FBS (Hyclone, Logan, UT, USA). For total cellular RNA isolation, macrophages were cultured in 6-well tissue culture dishes at 6.5 x 10 6 cells/well and incubated overnight, before gentle washing to remove non-adherent cell types followed by treatment for 4 h. In certain experiments where only TNFα activity was determined, macrophages were cultured in 12-well tissue culture dishes at 2.5 x 10 6 cells/well.
Isolation of total cellular RNA and Northern blot analysis
Macrophage cultures were subjected to the indicated treatments for 4 h in buffered RPMI medium containing 2% FBS. At the end of this period, culture supernatants were collected for the determination of TNFα activity. Macrophages were then solubilized in 1 ml of RNA-STAT60 (Tel-Test, Friendswood, TX, USA) and total cellular RNA was extracted according to the manufacturer's instructions. Northern blot analysis was performed using cDNA probes specific for TNFα and β-actin for the sequential probing of the Northern blots. 9 For the quantitation of genes, the PhosphorImager was used with Fast Scan software from Molecular Dynamics (Sunnyvale, CA, USA). All gene expression data were calculated by first normalizing for the housekeeping gene, β-actin. Values were then expressed as a percentage of the response induced by paclitaxel (Compound 1).
Measurement of TNFα secretion
Immunoreactive TNFα was detected in the culture supernatants of taxane-treated macrophages by an enzyme linked immunorsorbent assay (ELISA) according to the manufacturer's instructions (Genzyme Corporation, Cambridge, MA, USA).
RESULTS AND DISCUSSION
TNFα is a pivotal inflammatory mediator in endotoxicity and sepsis (reviewed by White et al. 23 ) and its production by macrophages has been used extensively to compare LPS with other inflammatory stimuli, including paclitaxel. Therefore, murine macrophages were treated with a series of taxane analogs and their capacity to induce TNFα secretion was first assessed. The taxane analogs utilized in these studies were paclitaxel and C-4 analogs (Figs 1 & 2) , analogs with modifications at C-7 (Fig. 3) , and C-2 pyridine carboxylate ester analogs (Fig.  4 ). Their relative activities in a standard anti-tumor cytotoxicity assay are provided in Table 1 .
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Based on their abilities to induce secretion of TNFα (Fig. 5, top panel) , the analogs can be categorized into three groups. Compounds 4, 5, 6 and 12 were strong inducers of TNFα secretion in a manner similar to compound 1, paclitaxel. Of these, compound 4 was somewhat less active, as evidenced by a markedly reduced capacity to stimulate TNFα secretion at a final concentration of 5 µM. Analogs 9 and 10 exhibited intermediate, but significant activity. The remaining analogs (2, 7, 8, 11, 14 and 15) exhibited very low TNFα-inducing activity or were completely inactive. Further analysis of these compounds at the level of TNFα gene expression (Fig. 5, bottom panel) , a more sensitive measure of LPSmimetic activity, confirmed and extended these findings. Notably, of the least active subset of TNFα-inducing analogs, compounds 14 and 15 were indeed able to elicit measurable TNFα gene expression, despite the fact that TNFα protein was only minimally detected.
Strongly active compounds 4, 5, and 6 are all analogs of paclitaxel in which the acetate at the C-4 position has been modified and the result is a C-4 cyclopropane carboxylic acid ester. 24, 25 Analog 4, which was found to be somewhat less active than paclitaxel at the level of TNFα secretion, is also de-acetylated at the C-10 position with respect to paclitaxel. In contrast, compound 2, the C-10 de-acetylated analog of paclitaxel, was essentially inactive at the level of both TNFα gene expression and protein production. This is in agreement with the results of an earlier study, 21 and with the new data, suggests that the extra carbons of the cyclopropane carboxylic acid ester at C-4 helps to retain or induce TNFα production. Compounds 5 and 6 have 3′N benzamide and 3′N t-butyl carbamate side chains, respectively, and display similar activity. This result is somewhat surprising in light of previous studies documenting the importance of the 3′N benzamide or substituted benzamides for TNFα production. 18, 26 Apparently, modifications such as the presence of C-4 cyclopropane carboxylate ester can over-ride the clear preference for a benzamide, rather than carbamate moiety at the 3′ nitrogen. Entry 3 in the table, docetaxel (Taxotere ® ), is an analog of paclitaxel that contains both the 3′N t-butyl carbamate side chain and a de-acetylated hydroxy group at position 10. Docetaxel has been found to be inactive in TNFα assays in previous studies. 17, 19 C-4 cyclopropane carboxylate esters of paclitaxel have previously been reported to possess greater potency than paclitaxel in tubulin polymerization and cytotoxicity assays. 24, 25 Analog 7, another member of this class, was inactive in the TNFα assay. This analog is the same as the strongly active analog 5, but contains an additional ethyl carbonate moiety formed from the 2′ hydroxy group of the side chain. It is clear that this modification has a dramatic negative effect on TNFα induction. The ethyl carbonate moiety at this position is known to eliminate tubulin polymerization properties. Taxane 2′-ethyl carbonates only show activity in assays where enzymatic hydrolysis to generate parent occurs. 27 Compound 12, the final strongly active compound, is deoxygenated at position 7 and, in addition, contains a 3′N t-butyl carbamate substituent in the side chain, rather than a 3′N benzamide found in paclitaxel. This analog is reported to be more potent than paclitaxel in cytotoxicity assays. 28 Therefore, it can be inferred that deoxygenation at position 7 facilitates the production of TNFα in this side chain series because the corresponding hydroxy analog, compound 13, has been reported in the literature to be a very weak inducer of TNFα production. 18 In agreement with this, the 7-deoxy analog of paclitaxel has been reported to be a more potent inducer of TNFα production than the parent. 21 Compound 9, 7-epi paclitaxel, showed a positive effect on TNFα levels, but was less potent than the parent compound, which suggests that the configuration of the 7 hydroxy group found in paclitaxel is better suited for optimal activity. This is in agreement with the literature. 21 As seen in compound 10, replacement of the 3′ phenyl of the side chain with a 2-furyl heterocycle reduces potency in the TNFα assay to a moderate level. Thus, the phenyl moiety is more desirable than the 2-furyl for TNFα induction in this series, an effect that is opposite to what has been reported previously for this analog in a cytotoxicity assay. 29 Fig. 4 . Analogs in which the C-2 benzoate is modified to provide different isomers of C-2 pyridine carboxylate esters are depicted.
Analogs 14 and 15 contain 2-and 3-pyridine carboxylate ester moieties, respectively, at the C-2 position, rather than a benzoate. These analogs both produce low levels of activity which are considerably less than that of the parent paclitaxel. This supports the previously advanced findings that modifications of the substituents on the C-1 or C-2 position of taxanes can have a large effect on TNFα production and other activities. 21 The pyridine carboxylate ester analogs have been previously reported to be less cytotoxic than the parent C-2 benzoate series. 30 An examination of the structures of the remaining analogs which induce little more than background levels of TNFα mRNA or protein demonstrate that some single modifications to the structure of paclitaxel essentially abolish activity. Compound 8, an analog in which the C-4 acetate has been converted to a larger C-4 benzoate, was inactive in the current study. In addition, this analog has also displayed considerably reduced potency in tubulin polymerization and cytotoxicity assays. 25 As mentioned above, compound 2, the 10-deacetyl analog of paclitaxel, also exhibited a markedly reduced ability to induce TNFα secretion or gene expression. However, this analog retains full potency in a tubulin polymerization assay, 21 lending support to earlier studies that proposed that taxane effects on microtubules and LPS-like activities are dissociable. In addition, the 3′(2-furyl)-3′N t-butyl carbamate side chain (analog 11) was found to be essentially inactive in the current TNFα production study, although this compound has previously been reported to be more potent than paclitaxel in tubulin polymerization and cellular proliferation assays. 31 The inactivity of this compound is consistent with the structure activity relationships, since, as mentioned above, the 3′N t-butyl carbamate side chain analog of paclitaxel, compound 13, has been reported to be inactive and the 2′furyl-containing side chain appears to have a negative effect on TNFα production. In summary, the induction of TNFα by taxane stimulation of murine macrophages is highly structure-dependent. Our findings significantly expand our understanding of the scope of the structure-activity relationships for the LPSmimetic activities of paclitaxel.
LPS-mimetic activities of taxane analogs in murine macrophages 265
Using a photo-activatable paclitaxel analog, which retains LPS-mimetic activity in murine macrophages, Bhat and co-workers 33 found that this derivative binds to murine CD18 on murine macrophage membranes, but not to human CD18. In addition, macrophages deficient in Mac-1 (CD11b/CD18) due to a targeted mutation in CD11b, responded to paclitaxel with markedly diminished expression of IL-12 p40 mRNA and anti-Mac-1 antibody (but not a control antibody) blocked both paclitaxel-and LPS-induced bioactive IL-12 secretion in normal murine macrophages. 33 Coupled with the findings of Ding and colleagues 34 that mice which express the Lps d allele (recently identified as a mutation in the gene that encodes the transmembrane signaling protein, TLR4 35, 36 ), the data suggest that these two molecules (e.g., Mac-1 and TLR4) may be necessary membrane targets for Taxol's LPS-mimetic activities in murine macrophages. We have previously proposed a model in which paclitaxel binds initially through CD18 (in the context of Mac-1, accounting for its apparent species specificity) and then interacts with TLR4 at the macrophage membrane 37 to elicit signaling for gene expression. One could readily envision the chemical alterations described herein which were found to reduce or eliminate paclitaxel signaling for induction of TNFα mRNA or protein to be the consequence of an altered interation of inactive paclitaxel analogs with one or both of these membrane-associated proteins. Clearly, development of advanced three-dimensional models will be important for future studies.
